<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354405</url>
  </required_header>
  <id_info>
    <org_study_id>PCLD 10-03</org_study_id>
    <nct_id>NCT01354405</nct_id>
  </id_info>
  <brief_title>Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)</brief_title>
  <acronym>RESOLVE</acronym>
  <official_title>The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effect of Lanreotide on polycystic liver and&#xD;
      kidneys in patients with autosomal dominant polycystic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this single center observational study is to assess the effect of lanreotide on&#xD;
      polycystic liver and kidney. This is achieved by assessing total liver and kidney volume, and&#xD;
      several urinary markers that could predict kidney damage or kidney dysfunction, such as GFR,&#xD;
      blood pressure, and urinary tubular damage markers and serum biomarker FGF23.&#xD;
&#xD;
      The investigators aim to include 43 patients affected by a polycystic liver due to ADPKD. The&#xD;
      duration of the trial will be 28 weeks. The treatment will be 24 weeks and the first&#xD;
      screening visit will take place four weeks before start of treatment. Eligible patients will&#xD;
      be invited to participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Liver volume</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in total liver volume between baseline and 24 weeks, as determined by CT volumetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney volume</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in kidney volume between baseline and 24 weeks, as determined by CT volumetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in GFR between baseline and 24 weeks, as determined by serum and 24 hrs urinary creatinine measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary tubular damage markers</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in urinary tubular damage markers between baseline and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in symptoms between baseline and 24 weeks, assessed by GI-questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in blood pressure between baseline and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in quality of life between baseline and 24 weeks, measured by EuroQoL-questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>All adverse events that occur during 24 weeks of treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Polycystic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Lanreotide</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide</intervention_name>
    <description>120 mg every 28 days intramuscular</description>
    <arm_group_label>Lanreotide</arm_group_label>
    <other_name>Somatuline</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ADPKD patients in Radboud University Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ADPKD with polycystic liver (&gt; 20 liver cysts)&#xD;
&#xD;
          -  Renal function MDRD &gt;40 ml/hr&#xD;
&#xD;
          -  Informed consent, patients are willing and able to comply with the study drug regimen&#xD;
             and all other study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Kidney transplantation&#xD;
&#xD;
          -  Renal failure requiring hemodialysis&#xD;
&#xD;
          -  Use of oral contraceptives or estrogen suppletion&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  History of cardiac/pulmonary disease; symptomatic gallstones, pancreatitis, etc&#xD;
&#xD;
          -  Intervention (aspiration or surgical intervention) within three months from baseline&#xD;
&#xD;
          -  Treatment with somatostatin analogues within three months from baseline&#xD;
&#xD;
          -  Mental illness that interferes with the patient ability to comply with the protocol&#xD;
&#xD;
          -  Drug or alcohol abuse within one year from baseline&#xD;
&#xD;
          -  Abnormal liver function tests, as determined by blood test (except isolated elevated&#xD;
             GGT and AP, which occurs frequently in PLD)&#xD;
&#xD;
          -  Clinical diagnosis of pancreatitis&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus, as determined by blood test and medical history&#xD;
&#xD;
          -  Use of drugs that can interact with lanreotide, such as cyclosporin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost PH Drenth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Hospital</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009 Nov;137(5):1661-8.e1-2. doi: 10.1053/j.gastro.2009.07.052. Epub 2009 Jul 29.</citation>
    <PMID>19646443</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

